Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MPI | P34949 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | DDO | Q99489 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.56 |
| ▸ | MAP2 | P11137 | 1/20 | 0.54 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709937 | 1.00 | MAPT (0.75) | MAPTKDM4EALDH1A1IDEMPI | |
| SCHEMBL15713617 | 0.87 | MAPK14 (0.63) | MAPTKDM4EALDH1A1IDEMPI | |
| SCHEMBL4455323 | 0.86 | MAPT (1.00) | MAPTKDM4EALDH1A1IDEMPI | |
| SCHEMBL28132803 | 0.83 | MAPT (0.71) | MAPTKDM4EALDH1A1IDEMPI | |
| SCHEMBL24095581 | 0.81 | KDM4E (0.79) | MAPTKDM4EALDH1A1MAP2 | |
| SCHEMBL25849861 | 0.81 | PIM1 (0.66) | MAPTKDM4EALDH1A1HPGDPADI4 | |
| SCHEMBL7811680 | 0.79 | KDM4E (0.70) | MAPTKDM4EALDH1A1PDE9AHPGD | |
| SCHEMBL1884123 | 0.79 | KDM4E (1.00) | MAPTKDM4EALDH1A1IDEMPI | |
| SCHEMBL8987076 | 0.79 | MAPT (0.60) | MAPTKDM4EALDH1A1PDE9ADAO | |
| SCHEMBL31179077 | 0.79 | MAPK1 (0.68) | MAPTKDM4EALDH1A1PDE9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-6126924-A | Light responsive self-tanning products and methods for use | SCALES-MEDEIROS VIRGINIA A (US) | 2000-10-03 | — | — | US | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC | 2022-11-17 | — | — | US | disclosed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10568877-B2 | Preparation and anti-HSV-1 application of quinolinone derivatives | OCEAN UNIVERSITY OF CHINA (CN) | 2020-02-25 | — | — | US | disclosed |
| EP-1011677-A1 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5972961-A | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES; SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0942723-A1 | 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5922735-A | CALCIUM-ACTIVATED POTASSIUM CHANNELS AND ARE USEFUL TREATING THE DISORDER RESPONSIVE TO THE OPENING OF THE POTASSIUM CHANNELS SUCH AS ISCHEMIA, CONVULSIONS, ASTHMA, IRRITABLE BOWEL SYNDROME, MIGRAINE, TRAUMATIC BRAIN INJURY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| US-5892045-A | 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1999009983-A1 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998023273-A1 | 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-4668627-A | 3-16-ISOCYANO-3,7-DIOXATRICYCLO/4.1.0.0.2,4/HEPT-4-YL/ PROPENOIC ACID | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4542154-A | 2188,3-(6-ISOCYANO-3,7-DIOXATRICYCLOE4.1.0.0.2.4)HEPT-4-YL) PROPENOIC ACID | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | MAPT 2118/4885KDM4E 4365/4885ALDH1A1 4556/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | MAPT 3552/4885KDM4E 3795/4885ALDH1A1 1371/4885 |
| US-10568877-B2 | Preparation and anti-HSV-1 application of quinolinone derivatives | RPL5, TOP1, TOP2A | MAPT 442/4885KDM4E 948/4885ALDH1A1 1996/4885 |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | PRKG2, PRKG1, CIT | MAPT 2118/4885KDM4E 4365/4885ALDH1A1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.